Alex Kadet
Alex Kadet is the Chief Business Officer at Gero, a physics-enabled biotechnology company targeting the root causes of age-related diseases through AI-driven drug discovery. He is also a Mentor and Counselor at the Longevity Biotech Fellowship, where he supports the building of revolutionary longevity biotechnology projects.
With over 10 years of experience in business development and strategic partnerships in the biotechnology sector, Alex has established himself as a leading figure in the longevity biotech space. He focuses on translating cutting-edge science into therapeutic solutions for aging and chronic diseases. Alex is at the forefront of biotechnology, dedicated to unraveling the complexities of aging and chronic diseases through human data and advanced physics-informed machine learning.
At Gero, Alex leads strategic partnerships and collaborations with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance their mission of targeting age-related diseases. The company’s approach has earned collaborations with leading institutions like Harvard Medical School, NYU, and the Roswell Park Cancer Center, as well as a strategic partnership with Pfizer to develop treatments for fibrotic diseases.
Under his leadership, Gero leverages its ML-enabled platform and drug discovery pipeline to develop novel therapeutics that address age-related diseases and slow the aging process itself. Watch Reversing Time: Q&A with Peter Fedichev, founder and CEO of Gero, and Alex Kadet, chief business officer.
In January 2023, Alex announced Gero’s research collaboration with Pfizer to apply Gero’s machine-learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data. Alex said, “We are excited to work with Pfizer, one of the world’s leading biopharmaceutical companies, to potentially identify targets against fibrotic diseases, which have a large unmet need.”
Alex has been instrumental in positioning Gero’s move from Russia and Singapore to the US, with operations mostly in the US now, as the company prepares to establish its headquarters in Palo Alto, California. The firm has raised more than $7.5 million to date, most recently in a $2.2 million Series A round that closed in 2020. Read Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases.
Since January 2023, Alex has served as a Mentor and Counselor at the Longevity Biotech Fellowship (LBF), a nonprofit organization supporting the building of new companies and attracting investments in revolutionary longevity biotechnology projects. In this role, he mentors entrepreneurs, scientists, and investors who are committed to solving aging and developing breakthrough therapies.
The LBF brings together industry-leading mentors, investors, and founders to accelerate progress in longevity biotech through intensive retreats, online programs, and ongoing community support. Alex is recognized as part of the Longevity Biotech Fellowship in the recent publication “Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity,” published in Aging Journal. Read Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity.
Alex is a thought leader in the longevity space, contributing articles on the philosophy and science of life extension. In 2020, he published Why Aren’t We Afraid of Death?: The First Step Toward Defeating Aging in the U.S. Transhumanist Party publication, where he explored the psychological and societal barriers to addressing aging as a treatable condition.
In the article, he argues that “the general lack of interest in treating aging comes from a lack of fear of aging, as humans tend not to be consciously afraid of death. Where there is no fear of a phenomenon, there is no aim to eliminate it.” Listen to Alex Kadet on immortality, death, transhumanism and future of humans.
Prior to his current roles, Alex served as Head of Business Development at Gero from 2020 to 2022, where he established the company’s strategic partnership framework and led international business development efforts. Before joining Gero, he was Head of Business Development (AI/ML & Human Data for Biotech) at Longenesis between 2019 and 2020, a data-driven biotech startup founded by Insilico Medicine and Bitfury.
At Longenesis, he reported to the CEO and led an international team of 6 business development associates, successfully entering the Asian market by establishing a legal framework for biomedical data collection in collaboration with a leading Korean law firm. He negotiated the company’s first international contracts and established strategic partnerships with leading Korean genome sequencers.
Alex also served as Vice President of Business Development at Open Longevity from December 2018 to July 2019, a focused research organization (FRO) dedicated to accelerating the progress of science to end age-related diseases. In this role, he collaborated with the CSO to recruit PhDs and MDs, implemented remote management frameworks, and managed the scientific team to release an updated version of the Diagnostics of Aging Biomarkers Panel.
From June 2022 to January 2023, he was an On Deck Longevity Biotech Fellow at On Deck, participating in a continuous community for people to build, join, or invest in revolutionary longevity biotechnology startups.
From 2014 to 2018, Alex was Cofounder and Chief Business Development Officer at Healthy Products, a $5M ARR FoodTech company focused on R&D and distributing `functional and medicinal food and beverage products. He was responsible for strategy, marketing, and business development, establishing multi-year strategic collaborations with State Technology University and launching production under the company’s own brand.
Early in his career, Alex worked as a Consultant within the Tax Function Effectiveness Team at PwC in 2014, where he saved millions of dollars in taxes annually for one of the world’s largest public oil companies by developing business logic for IT solutions that automated tax risk analysis.
Alex earned his Certificate in Global Business and International Management from FH JOANNEUM – International Management in Austria from 2012 to 2013. He completed the HMX Pro program in Molecular Biology, Biochemistry, and Genetics at Harvard Medical School from 2023 to 2024. Alex earned his Bachelor’s Degree of Science in Economics and Management from Voronezh State University School of Economics from 2010 to 2014, where he graduated as the top student in 5 years (classes 2009–2014) and was an Oxford Fund Scholar and Potanin’s Scholar.
He attended the Nikolai G. Basov Specialized School of Physics and Mathematics from 2000 to 2010, a specialized school named after the Nobel Prize Laureate and inventor of the laser and maser. Alex holds several professional certifications, including the Advanced Business Development Course (therapeutics) from EBD Academy (issued November 2021) and Drug Discovery from the University of California San Diego via Coursera (issued September 2020).
Read Why Aren’t We Afraid of Death?: The First Step Toward Defeating Aging and Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity. Listen to Alex Kadet on immortality, death, transhumanism and future of humans.
Visit his LinkedIn profile. Follow him on Facebook, Instagram, and X.